18:12 WRAPX After Hours Summary: YUME +17.2%, TCX +15.4%, BORN +13.6%, PRCP -26.2%, FENG -17.1%, MM -15.2%, CSCO -10.8% following earnings/guidance After Hours Gainers:
Companies trading higher in after hours in reaction to earnings: YUME +17.2%, TCX +15.4%, BORN +13.6%, CGIX +6.8%, JST +5.9%, OINK +4.7%, KGC +1.4%, NTAP +1.4%, LOV +0.3%
Companies trading higher in after hours in reaction to news: NVAX +3.1% (New England Journal of Medicine publishes positive data from clinical trial of Novavax' vaccine against H7N9 avian flu), MEG +2.8% (Berkshire disclosed 5.5% active stake in amended 13D filing), AFL +1.1% (Board of Directors increased shares authorized for repurchase by 40 mln), BWA +0.6% (approved a two-for-one stock split effected in the form of a stock dividend on the company's common stock), SPW +0.5% (announces U.S. qualified pension plan actions; expected to reduce pension obligations by ~$800 mln)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings: PRCP -26.2%, FENG -17.1%, MM -15.2%, CSCO -10.8%, CRRS -4.4%, AFCE -3.8%, SEAS -1%, RMAX -0.9%, XONE -0.5%
Companies trading lower in after hours in reaction to news: TWGP -6.9% (filed to delay the filing of Form 10-Q), AH -4.0% (provided business and restatement update; appoints two new board members and authorizes $50 mln share repurchase program), GWR -3.2% (announced sale of ~5.98 mln shares of common stock by Carlyle Investment Funds), THRX -2.0% (disclosed TD-9855 did not meet the primary efficacy endpoint in Phase 2 study in adult patients with ADHD), END -1.5% (closed on the sale of 50% of its upstream and midstream assets in the Pennsylvania Marcellus and formed a joint venture with Samson Energy), SINA -0.7% (announced proposed offering of $600 mln convertible senior notes and concurrent $100 mln share repurchase)
7:05 NVAX Novavax: New England Journal of Medicine publishes positive data from clinical trial of Novavax' vaccine against H7N9 avian flu (2.91 +0.06)
Co announced that positive clinical data for the company's virus-like particle (VLP) vaccine candidate against A(H7N9) influenza were published online in the Correspondence section of The New England Journal of Medicine. The correspondence can be found at: http://www.nejm.org/doi/full/10.1056/NEJMc1313186 and will appear in the December 26, 2013 print edition. The study, conducted in 284 adult male and female subjects, examined the safety and immunogenicity of two administrations of Novavax' A(H7N9) VLP vaccine candidate on day 0 and day 21. Subjects were administered either placebo, 15 or 45 µg of vaccine alone, or 5 or 15µg of vaccine with either 30 or 60 ISCO units of the saponin-based ISCOMATRIX adjuvant, developed by CSL Limited in Australia. Serology was assessed at Days 0, 21 and 35 post-first immunization. The Novavax A(H7N9) VLP vaccine candidate was generally well tolerated, and the safety was in line with the company's previous findings with its influenza VLP antigens using ISCOMATRIX adjuvant. Data highlights: 81% of 5ug adjuvanted vaccine recipients had protective HAI levels 97% of 5ug adjuvanted vaccine recipients had anti-neuraminidase antibody responses Protective levels achieved from vaccinations within 116 days of the announced outbreak of novel lethal H7N9 virus Dose-sparing formulation shows significant potential utility in the event of a pandemic
Market Data 
Markets 
AI
